Science

Jarushka Naidoo: Brentuximab Vedotin and Pembro in PD-1-Pretreated NSCLC and Melanoma

Jarushka Naidoo/X

Mar 16, 2025, 15:00

Jarushka Naidoo: Brentuximab Vedotin and Pembro in PD-1-Pretreated NSCLC and Melanoma

Jarushka Naidoo, Full Professor and Consultant Medical Oncologist at Royal College of Surgeons in Ireland, shared a post on X about a paper by Sylvia Lee et al. published in Clinical Cancer Research:

“Ph II Trial Brentuximab Vedotin (anti-CD30 ADC) and Pembro in PD-1–Pretreated NSCLC and Melanoma:

2ndary refractory NSCLC (n=43): ORR 14%, mPFS 5.8m, mOS 14.4m
2ndary refactory melanoma (n=41): ORR: 24%, mPFS 4.4m mOS 21.9m.”

“Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma”

Authors: Sylvia Lee, Omid Hamid, Robert Jotte, Yousef Zakharia, Theresa Medina, Jason Berndt, Brian O’Connor, Kapil Rathi, Eeman Shaikh, Charles Lance Cowey et al.

Jarushka Naidoo: Brentuximab Vedotin and Pembro in PD-1-Pretreated NSCLC and Melanoma

More posts featuring Jarushka Naidoo.

Brian O’Connor cancer Charles Lance Cowey Eeman Shaikh Jarushka Naidoo Jason Berndt Kapil Rathi Melanoma Metastatic Cutaneous Melanoma non small cell lung cancer NSCLC Omid Hamid OncoDaily Oncology Robert Jotte Sylvia Lee Theresa Medina Yousef Zakharia

Bente Mikkelsen Appointed as Director of Global Engagement Strategies at St. Jude Children's Research Hospital

Audrey Evans - mother of neuroblastoma, a force for good in the world

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer

Kimryn Rathmell was Awarded 2025 ACS Medal of Honor

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer